ARTICLE | Cover Story
Rational approach to Xtandi resistance
May 9, 2013 7:00 AM UTC
A group led by researchers at the Memorial Sloan-Kettering Cancer Center has identified a mutation in the androgen receptor that could drive resistance to second-generation antiandrogen drugs such as
Medivation Inc.'s Xtandi enzalutamide. The team's subsequent rational drug design studies yielded a series of molecules that could overcome the resistance mechanism.1...